236 related articles for article (PubMed ID: 12491512)
1. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.
Montillo M; Tedeschi A; O'Brien S; Di Raimondo F; Lerner S; Ferrajoli A; Morra E; Keating MJ
Cancer; 2003 Jan; 97(1):114-20. PubMed ID: 12491512
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
[TBL] [Abstract][Full Text] [Related]
3. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
[TBL] [Abstract][Full Text] [Related]
4. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
Robak T; Blonski JZ; Wawrzyniak E; Gora-Tybor J; Palacz A; Dmoszynska A; Konopka L; Warzocha K; Jamroziak K
Cancer; 2009 Jan; 115(1):94-100. PubMed ID: 19025975
[TBL] [Abstract][Full Text] [Related]
5. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
Robak T; Smolewski P; Cebula B; Grzybowska-Izydorczyk O; Błoński JZ
Eur J Haematol; 2007 Aug; 79(2):107-13. PubMed ID: 17635235
[TBL] [Abstract][Full Text] [Related]
6. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
Laurencet F; Ballabeni P; Rufener B; Hess U; Cerny T; Fey M; Luthi JM; Plancherel C; Zulian GB;
Acta Haematol; 2007; 117(1):40-7. PubMed ID: 17095858
[TBL] [Abstract][Full Text] [Related]
7. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
[TBL] [Abstract][Full Text] [Related]
9. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
[TBL] [Abstract][Full Text] [Related]
12. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G
Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
[TBL] [Abstract][Full Text] [Related]
13. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
O'Brien S; Kantarjian H; Estey E; Koller C; Robertson B; Beran M; Andreeff M; Pierce S; Keating M
N Engl J Med; 1994 Feb; 330(5):319-22. PubMed ID: 7904047
[TBL] [Abstract][Full Text] [Related]
14. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia.
Robak T; Błoński JZ; Kasznicki M; Góra-Tybor J; Dwilewicz-Trojaczek J; Stella-Hołowiecka B; Wołowiec D
Hematol J; 2002; 3(5):244-50. PubMed ID: 12391542
[TBL] [Abstract][Full Text] [Related]
15. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
17. A phase I and II study of pentostatin (Nipent) with cyclophosphamide for previously treated patients with chronic lymphocytic leukemia.
Weiss MA
Semin Oncol; 2000 Apr; 27(2 Suppl 5):41-3. PubMed ID: 10877051
[TBL] [Abstract][Full Text] [Related]
18. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
Byrd JC; Peterson BL; Gabrilove J; Odenike OM; Grever MR; Rai K; Larson RA;
Clin Cancer Res; 2005 Jun; 11(11):4176-81. PubMed ID: 15930354
[TBL] [Abstract][Full Text] [Related]
19. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM
J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
